At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 281 enrolled
Drug / intervention
LY3437943 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
In Brief
A Phase 2 clinical trial evaluating LY3437943, Dulaglutide, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 281 participants across 43 sites in 2 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionJul 2022
Study CompletionOct 2022
TodayJul 2026
First PostedApr 30, 2021
Enrollment StartMay 13, 2021
Primary CompletionJul 8, 2022
Study CompletionOct 27, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.2 years ago
Interventions
LY3437943drug
Administered SC
Dulaglutidedrug
Administered SC
Placebodrug
Administered SC